Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 19 de 19
Filter
1.
J Pediatr Endocrinol Metab ; 34(8): 1017-1022, 2021 Aug 26.
Article in English | MEDLINE | ID: mdl-34162028

ABSTRACT

OBJECTIVES: Hereditary fructose intolerance (HFI) is an autosomal recessive disorder caused by a deficiency in aldolase B that can result in hypoglycemia, nausea, vomiting, abdominal pain, liver and kidney dysfunction, coma, and even death. This study aims to represent the clinical features and molecular genetic analysis data of the patients diagnosed with HFI in our study population. METHODS: The medical records of the 26 patients with HFI were evaluated retrospectively. Age, gender, clinical findings, metabolic crises, and the results of molecular analyses were recorded. RESULTS: The patients with HFI had a good prognosis and the aversion to sugar-containing foods was the main complaint. Seven different variants were identified in the Aldolase B (ALDOB) gene in HFI patients. The most frequent mutations were p.Ala150Pro, p.Ala175Asp had a prevalence of 61 and 30%, respectively, in agreement with the literature and other known variants were found with minor frequencies c.360-363del4(3.8%), p.Asn335Lys(3.8%), and three novel mutations c.113-1_15del4 (3.8%), p.Ala338Val(7.6%), and p.Asp156His(3.8%) were identified at a heterozygous, homozygous, or compound heterozygous level. CONCLUSIONS: This study results revealed three novel mutations in patients with HFI. On the basis of age of presentation, clinical symptoms, and metabolic crisis, there was no clear-cut genotype-phenotype correlation. This article also demonstrates the importance of screening suspected infants in cases of acute liver failure for prompt diagnosis and treatment of HFI.


Subject(s)
Fructose Intolerance/epidemiology , Fructose-Bisphosphate Aldolase/genetics , Genetic Predisposition to Disease , Medical Records/statistics & numerical data , Mutation , Adolescent , Adult , Child , Child, Preschool , Female , Follow-Up Studies , Fructose Intolerance/genetics , Fructose Intolerance/pathology , Heterozygote , Homozygote , Humans , Infant , Male , Middle Aged , Prognosis , Retrospective Studies , Turkey/epidemiology , Young Adult
2.
Cell Mol Life Sci ; 77(9): 1709-1719, 2020 May.
Article in English | MEDLINE | ID: mdl-31713637

ABSTRACT

Hereditary fructose intolerance (HFI) is a rare inborn disease characterized by a deficiency in aldolase B, which catalyzes the cleavage of fructose 1,6-bisphosphate and fructose 1-phosphate (Fru 1P) to triose molecules. In patients with HFI, ingestion of fructose results in accumulation of Fru 1P and depletion of ATP, which are believed to cause symptoms, such as nausea, vomiting, hypoglycemia, and liver and kidney failure. These sequelae can be prevented by a fructose-restricted diet. Recent studies in aldolase B-deficient mice and HFI patients have provided more insight into the pathogenesis of HFI, in particular the liver phenotype. Both aldolase B-deficient mice (fed a very low fructose diet) and HFI patients (treated with a fructose-restricted diet) displayed greater intrahepatic fat content when compared to controls. The liver phenotype in aldolase B-deficient mice was prevented by reduction in intrahepatic Fru 1P concentrations by crossing these mice with mice deficient for ketohexokinase, the enzyme that catalyzes the synthesis of Fru 1P. These new findings not only provide a potential novel treatment for HFI, but lend insight into the pathogenesis of fructose-induced non-alcoholic fatty liver disease (NAFLD), which has raised to epidemic proportions in Western society. This narrative review summarizes the most recent advances in the pathogenesis of HFI and discusses the implications for the understanding and treatment of fructose-induced NAFLD.


Subject(s)
Fructose Intolerance/pathology , Fructose/adverse effects , Genetic Predisposition to Disease , Non-alcoholic Fatty Liver Disease/pathology , Animals , Fructose/metabolism , Fructose Intolerance/drug therapy , Fructose Intolerance/etiology , Humans , Mice , Non-alcoholic Fatty Liver Disease/chemically induced , Non-alcoholic Fatty Liver Disease/drug therapy
3.
Rom J Morphol Embryol ; 58(3): 1109-1113, 2017.
Article in English | MEDLINE | ID: mdl-29250698

ABSTRACT

Celiac disease (CD) has been associated with several genetic and immune disorders, but association between CD and hereditary fructose intolerance (HFI) is extremely rare. HFI is an autosomal recessive disease caused by catalytic deficiency of aldolase B (fructose-1,6-bisphosphate aldolase). We report the case of a 5-year-old boy suffering from CD, admitted with an initial diagnosis of Reye's-like syndrome. He presented with episodic unconsciousness, seizures, hypoglycemia, hepatomegaly and abnormal liver function. The patient has been on an exclusion diet for three years, but he still had symptoms: stunting, hepatomegaly, high transaminases, but tissue transglutaminase antibodies were negative. Liver biopsy showed hepatic steatosis and mitochondrial damage. The dietary history showed an aversion to fruits, vegetables and sweet-tasting foods. The fructose tolerance test was positive, revealing the diagnostic of hereditary fructose intolerance. Appropriate dietary management and precautions were recommended. The patient has been symptom-free and exhibited normal growth and development until 10 years of age.


Subject(s)
Carbohydrate Metabolism/genetics , Celiac Disease/complications , Celiac Disease/genetics , Fructose Intolerance/genetics , Celiac Disease/pathology , Child, Preschool , Fructose Intolerance/pathology , Humans , Male
4.
Expert Rev Clin Immunol ; 9(6): 577-87, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23730887

ABSTRACT

Various types of excipients are added to immunoglobulin preparations to stabilize the product and prevent aggregation and dimer formation. These excipients, which are also called stabilizers or additives, are not inert chemicals and may have clinical implications. This is one reason why immunoglobulin products are not interchangeable. Herein, immunoglobulin preparation, excipient types and the differences among sugar stabilizers and the amino acids, glycine and proline as excipients, are presented. Preclinical studies that unravel the complexities of dimer reduction are summarized. Details of patient considerations with respect to excipient content are outlined focusing on patients with renal insufficiency, diabetes, corn allergy, hereditary fructose intolerance, inborn errors of proline metabolism, DiGeorge Syndrome and neuropsychiatric disorders associated with hyperprolinemia. Excipients are essential components of immunoglobulin preparations and their presence should be a consideration when matching patient needs to product characteristics.


Subject(s)
Excipients , Immunoglobulins/therapeutic use , Diabetes Mellitus/drug therapy , Diabetes Mellitus/pathology , Drug Stability , Food Hypersensitivity/drug therapy , Food Hypersensitivity/pathology , Fructose Intolerance/drug therapy , Fructose Intolerance/pathology , Humans , Immunoglobulins/adverse effects , Renal Insufficiency/drug therapy , Renal Insufficiency/pathology
6.
Am J Gastroenterol ; 104(1): 102-9, 2009 Jan.
Article in English | MEDLINE | ID: mdl-19098857

ABSTRACT

OBJECTIVES: We sought to determine the quantitative expression of the high-affinity Fc receptor (CD64) on polymorphonuclear neutrophils (PMNs) in inflammatory and functional conditions of the intestine and investigated its correlation with clinical and biological parameters of inflammation. METHODS: The quantitative expression of CD64 was determined by fluorescence-activated cell sorting analysis in patients with active or inactive inflammatory bowel disease (IBD, n=76), infectious enterocolitis, lactose and/or fructose intolerance, and healthy subjects. RESULTS: The quantitative expression of CD64 in patients with active IBD (3,398+/-3,589 molecules per PMN, n=27) was significantly higher than in healthy subjects (607+/-265, n=28, P<0.001) or in patients with lactose/fructose intolerance (531+/-150, n=32, P<0.001). The expression of CD64 correlated significantly with C-reactive protein (CRP, 0.65, P<0.0001), Crohn's disease activity index (CDAI, 0.53, P<0.0001), and colitis activity index (CAI, 0.63, P<0.0001) in patients with IBD. With a cutoff point of 800, CD64 had a sensitivity of 88% and a specificity of 93% in discriminating between lactose/fructose intolerance and active IBD. The quantitative expression of CD64 in patients with infectious enterocolitis (19,190+/-8,920, n=22) was significantly higher than in patients with active IBD (P<0.001). With a cutoff point of 10,000, CD64 showed a sensitivity of 96% and a specificity of 97% in discriminating between infectious enterocolitis and active IBD. CONCLUSIONS: CD64 could serve as a valuable tool to discriminate between IBD, infectious enterocolitis, and functional intestinal disorders.


Subject(s)
Inflammatory Bowel Diseases/diagnosis , Receptors, IgG/analysis , Adult , Bacterial Infections/diagnosis , Bacterial Infections/immunology , Biomarkers/analysis , Enterocolitis/diagnosis , Enterocolitis/immunology , Enterocolitis/microbiology , Enterocolitis/pathology , Female , Flow Cytometry , Fructose Intolerance/diagnosis , Fructose Intolerance/immunology , Fructose Intolerance/pathology , Humans , Immunohistochemistry , Inflammatory Bowel Diseases/immunology , Inflammatory Bowel Diseases/pathology , Intestinal Mucosa/pathology , Lactose Intolerance/diagnosis , Lactose Intolerance/immunology , Lactose Intolerance/pathology , Male , Middle Aged , Neutrophils/immunology , Neutrophils/pathology , Sensitivity and Specificity
7.
J Pediatr Gastroenterol Nutr ; 47(3): 303-8, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18728526

ABSTRACT

OBJECTIVES: We determined the occurrence of fructose malabsorption in pediatric patients with previous diagnoses of abdominal pain caused by a functional bowel disorder, whether the restriction of fructose intake changes the reporting of symptoms, the role of fructose dosage, and the severity of resultant symptoms. PATIENTS AND METHODS: We administered a fructose breath test to children presenting with persistent unexplained abdominal pain. Patients randomly received 1, 15, or 45 g fructose, and breath hydrogen was measured for 3 hours after ingestion. Test results were positive when breath hydrogen was 20 ppm greater than baseline and was accompanied by gastrointestinal symptoms. RESULTS: A total of 32 patients was enrolled, and none of the 9 who received 1 g had positive results. Three of 10 who received 15 g and 8 of 13 who received 45 g had positive results. All patients with positive test results restricted their fructose intake. Among the group with positive results, 9 of 11 had rapid improvement of their gastrointestinal symptoms. After 2 months, all 9 patients continued to report improvement. CONCLUSIONS: We concluded that fructose malabsorption may be a significant problem in children and that management of dietary intake can be effective in reducing gastrointestinal symptoms.


Subject(s)
Abdominal Pain/etiology , Fructose Intolerance/complications , Fructose Intolerance/diagnosis , Fructose/pharmacokinetics , Abdominal Pain/diagnosis , Abdominal Pain/pathology , Adolescent , Area Under Curve , Breath Tests/methods , Child , Cross-Over Studies , Dose-Response Relationship, Drug , Female , Fructose/metabolism , Fructose Intolerance/pathology , Humans , Intestinal Absorption , Male , Severity of Illness Index
9.
Baillieres Clin Gastroenterol ; 4(1): 61-78, 1990 Mar.
Article in English | MEDLINE | ID: mdl-2207353

ABSTRACT

Hereditary fructose intolerance (HFI) is an inborn error of carbohydrate metabolism that is inherited as an autosomal recessive condition. The disease is caused by a catalytic deficiency of aldolase B and is characterized by severe abdominal symptoms and hypoglycaemia which follow the ingestion of fructose, sucrose or sorbitol. The exact prevalence of HFI in different populations is unknown but studies from Switzerland suggest a disease frequency of about 1 in 20,000 live births, thus predicting a carrier frequency of greater than 1% and a gene prevalence that approaches polymorphic frequency. It is notable that many patients who endure severe symptoms during early infancy develop a marked aversion to harmful foodstuffs and thereby survive to adulthood. Although exposure to fructose may prove to be fatal in this disorder, institution of a strict exclusion diet is curative. HFI, when treated rigorously after diagnosis, is thus compatible with a long and healthy life. HFI vividly illustrates the interplay of dietary factors and heredity in the development of human disease. The recent identification of genetic lesions that cause this disorder further demonstrates the remarkable clinical benefits that may accrue from the study of the molecular basis of inherited diseases and its population genetics: it is now possible to detect asymptomatic disease carriers and diagnose the disorder in affected families by non-invasive analysis of small samples of genomic DNA. Moreover, the systematic investigation of natural mutations in the human gene for aldolase B has allowed regions that are critical for catalytic function of this enzyme to be identified as part of an extended study of its molecular biology.


Subject(s)
Fructose Intolerance/genetics , Adult , Fructose Intolerance/diagnosis , Fructose Intolerance/pathology , Fructose-Bisphosphate Aldolase/genetics , Genes , Genetic Carrier Screening , Genotype , Humans , Infant , Mutation , Polymerase Chain Reaction
10.
Zentralbl Allg Pathol ; 134(3): 265-74, 1988.
Article in German | MEDLINE | ID: mdl-3188689

ABSTRACT

Bioptic material of the small intestine is suitable for short-time in-vitro incubation in 3H-thymidine labelled medium followed by autoradiography. Histological and autoradiographic investigations of the small intestine of 45 children yielded the following characteristic findings: 1. 93 per cent of the healthy controls (n = 14) showed normal mucous membrane (Type I according to Shmerling) and a mean 3H-thymidine labelling index of 13 per cent. 2. Normal histological findings but a mean autoradiographic labelling index of 22 per cent were recorded from 87 per cent of children with cow's milk or fructose incompatibility (n = 12). 3. Mucous membrane of Shmerling Type I and a labelling index of enterocytes of 32 per cent was recorded from 50 per cent of children with coeliac disease (n = 19) after diet periods of seven or three to five months. Other children with coeliac disease but without therapy up to that time showed in 80 per cent the Shmerlings Type III and in 20 per cent Type II accompanied by the highest labelling index of 35 per cent. The increase of proliferative activity of enterocytes in coeliac disease shown by autoradiography and histological observations (villous atrophy) suggested an increased rate of cell death which led to the need for high cell replacement. This autoradiographic method used complementarily to usual histological diagnosis, has proved to help saving an enormous amount of time in the diagnosis of coeliac disease.


Subject(s)
Intestine, Small/pathology , Malabsorption Syndromes/pathology , Adolescent , Animals , Autoradiography , Biopsy , Celiac Disease/pathology , Child , Child, Preschool , Food Hypersensitivity/pathology , Fructose Intolerance/pathology , Humans , Infant , Milk/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL
...